Trial Profile
Exploratory study to evaluate changes in inflammatory pattern and analysis for serum biomarkers in patients with active, moderate-to-severe hidradenitis suppurativa after 2-week and 6-week treatment with a TNF-alpha Inhibitor.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Sep 2020
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Biomarker; Pharmacodynamics
- 07 Sep 2020 Status changed from recruiting to completed.
- 17 Nov 2017 New trial record